Search - tctmd.com

Displaying 81 - 100 of 197

Sort: Relevancy | Date

News Opinion CV Team Dispatch

August 2023 News Roundup

L.A. McKeown

August 01, 2023

News Daily News

CVD Risk Reduction With Exercise Also Seen in ‘Weekend Warriors’

Michael O'Riordan

July 24, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

Todd Neale

July 17, 2023

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

News Opinion CV Team Dispatch

June 2023 News Roundup

L.A. McKeown

June 01, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2023

Shelley Wood

April 28, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Opinion CV Team Dispatch

April 2023 News Roundup

L.A. McKeown

April 01, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

News Opinion CV Team Dispatch

March 2023 News Roundup

L.A. McKeown

March 15, 2023

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

L.A. McKeown

March 14, 2023

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Opinion CV Team Dispatch

February 2023 News Roundup

L.A. McKeown

February 15, 2023

News Daily News

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

L.A. McKeown

February 02, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

Advertisement

August 2023 News Roundup

CVD Risk Reduction With Exercise Also Seen in ‘Weekend Warriors’

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

June 2023 News Roundup

With New LDL Goalposts in FH, Combo Therapy Must Start Early

TCTMD’s Top 10 Most Popular Stories for April 2023

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

April 2023 News Roundup

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 2023 News Roundup

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

February 2023 News Roundup

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content